A cost-consequence analysis comparing three cardiac ablation strategies for the treatment of paroxysmal atrial fibrillation.
Mileen R D van de KarLukas R C DekkerInes TimmermannsDomenico Della RoccaGian-Battista ChierchiaLise Da Riis-VestergaardSteffen UffenordeJohn MorganJulian ChunPublished in: Journal of medical economics (2024)
Background and aimsCardiac ablation is a well-established method for treating atrial fibrillation (AF). Pulsed field ablation (PFA) is a non-thermal therapeutic alternative to radiofrequency ablation (RFA) and cryoballoon ablation (CRYO). PFA uses high-voltage electric pulses to target cells. The present analysis aims to quantify the costs, outcomes, and resources associated with these three ablation strategies for paroxysmal AF.MethodsReal-world clinical data were prospectively collected during index hospitalization by three European medical centers (Belgium, Germany, the Netherlands) specialized in cardiac ablation. These data included procedure times (pre-procedural, skin-to-skin and post-procedural), resource use, and staff burden. Data regarding complications associated with each of the three treatment options and redo procedures were extracted from the literature. Costs were collected from hospital economic formularies and published cost databases. A cost-consequence model from the hospital perspective was built to estimate the impact of the three treatment options in terms of effectiveness and costs.ResultsAcross the three centers, N = 91 patients were included over a period of 12 months. A significant difference was seen in pre-procedural time (mean ± SD, PFA: 13.6 ± 3.7 min, CRYO: 18.8 ± 6.6 min, RFA: 20.4 ± 6.4 min; p < 0.001). Procedural time (skin-to-skin) was also different across alternatives (PFA: 50.9 ± 22.4 min, CRYO: 74.5 ± 24.5 min, RFA: 140.2 ± 82.4 min; p < 0.0001). The model reported an overall cost of €216,535 per 100 patients treated with PFA, €301,510 per 100 patients treated with CRYO and €346,594 per 100 patients treated with RFA. Overall, the cumulative savings associated with PFA (excluding kit costs) were €850 and €1,301 per patient compared to CRYO and RFA, respectively.ConclusionPFA demonstrated shorter procedure time compared to CRYO and RFA. Model estimates indicate that these time savings result in cost savings for hospitals and reduce outlay on redo procedures. Clinical practice in individual hospitals varies and may impact the ability to transfer results of this analysis to other settings.
Keyphrases
- radiofrequency ablation
- atrial fibrillation
- high resolution
- catheter ablation
- electron microscopy
- healthcare
- clinical practice
- electronic health record
- left atrial appendage
- big data
- soft tissue
- heart failure
- left atrial
- randomized controlled trial
- left ventricular
- minimally invasive
- wound healing
- oral anticoagulants
- direct oral anticoagulants
- ejection fraction
- mass spectrometry
- skeletal muscle
- oxidative stress
- patient reported outcomes
- insulin resistance
- aortic valve replacement
- signaling pathway
- smoking cessation
- percutaneous coronary intervention
- pi k akt
- patient reported